Drug Name Abilify

Rimonabant (also known as SR141716; trade names Acomplia, Bethin, Monaslim, Remonabent, Riobant, Slimona, Rimoslim, Zimulti, and Riomont) is an anorectic antiobesity drug. It is an inverse agonist for the cannabinoid receptor CB1. Its main effect is reduction in appetite. Rimonabant was the first selective CB1 receptor blocker to be approved for use anywhere in the world.
After ingestion, it is converted to its active form. The active form of hydroxyzine is a drug called cetirizine (Zyrtec). Although, both hydroxyzine and cetirizine act as antihistamines, hydroxyzine causes more sedation than cetirizine. The FDA approved hydroxyzine in 1956.

 

Despite a recent recommendation that hemoglobin A1c (HbA1c) be used as a standard diagnostic test for diabetes, the proposed diagnostic criteria fail to pick up a significant number of cases of diabetes and prediabetes, investigators reported at the 70th Annual Scientific Sessions of the American Diabetes Association.
Hydroxyzine is an antihistamine with anticholinergic (drying) and sedative properties that is used to treat allergic reactions. The body releases histamine during several types of allergic reactions and--to a lesser extent--during some viral infections, such as the common cold. When histamine binds to its receptors on cells, it causes the cells to release chemical messengers that lead to sneezing, itching, and increased mucus production.